Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.78 USD
Change Today 0.00 / 0.00%
Volume 585.3K
BCRX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biocryst pharmaceuticals inc (BCRX) Snapshot

Open
$9.64
Previous Close
$9.78
Day High
$9.81
Day Low
$9.45
52 Week High
08/11/14 - $14.62
52 Week Low
05/8/14 - $7.29
Market Cap
708.6M
Average Volume 10 Days
641.4K
EPS TTM
$-0.63
Shares Outstanding
72.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOCRYST PHARMACEUTICALS INC (BCRX)

biocryst pharmaceuticals inc (BCRX) Related Businessweek News

No Related Businessweek News Found

biocryst pharmaceuticals inc (BCRX) Details

BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE. The company’s product candidates also comprise BCX4430, an RNA dependent-RNA polymerase inhibitor that is in Phase I clinical trial for treating Filoviruses, including Ebola and Marburg viruses; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir in Japan, Taiwan, and South Korea. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

50 Employees
Last Reported Date: 03/2/15
Founded in 1986

biocryst pharmaceuticals inc (BCRX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $633.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $461.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $503.8K
Senior Vice President of Drug Discovery
Total Annual Compensation: $460.8K
Vice President, General Counsel and Corporate...
Total Annual Compensation: $326.3K
Compensation as of Fiscal Year 2014.

biocryst pharmaceuticals inc (BCRX) Key Developments

BioCryst Pharmaceuticals Receives Development Contract for Antiviral Drug from BARDA

BioCryst Pharmaceuticals, Inc. has received a contract for the continued development of BCX4430, an antiviral drug to treat diseases caused by RNA pathogens, including filoviruses, from the Biomedical Advanced R&D Authority, or BARDA, within the US Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, or ASPR. This ASPR/BARDA contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0 million. The scope of work under the base contract mainly focuses on drug manufacturing, including process improvement, scale up and manufacture of BCX4430 in the U.S over an 18 month period. The BCX4430 produced under this contract is expected to be used in clinical studies and non-clinical toxicology studies supporting the filing of a New Drug Application (NDA) with the FDA for both intravenous (i.v.) and intramuscular (i.m.) formulations of BCX4430.

BioCryst Wins BCX4430 Advanced Development Contract

BioCryst Pharmaceuticals, Inc. announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of BCX4430 as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This ASPR/BARDA contract includes a base contract of $12.1 million to support BCX4430 drug manufacturing, as well as $22.9 million in additional development options that can be exercised by the Government, bringing the potential value of the contract to $35.0 million.

BioCryst Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 12:10 PM

BioCryst Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 12:10 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCRX:US $9.78 USD 0.00

BCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Daiichi Sankyo Co Ltd ¥1,970 JPY +18.50
Dyax Corp $27.97 USD -0.46
Gilead Sciences Inc $101.38 USD -1.96
GlaxoSmithKline PLC 1,576 GBp -20.50
Shire PLC 5,430 GBp -30.00
View Industry Companies
 

Industry Analysis

BCRX

Industry Average

Valuation BCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 51.7x
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 44.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCRYST PHARMACEUTICALS INC, please visit www.biocryst.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.